Halozyme Therapeutics
Stock Forecast, Prediction & Price Target
Halozyme Therapeutics (HALO) stock Price Target by analysts
$52
Potential downside: -25.71%
Halozyme Therapeutics price prediction
What is Halozyme Therapeutics stock analysts` prediction?
Halozyme Therapeutics stock forecast: Based on 1 Wall Street analysts` predicted price targets for Halozyme Therapeutics in the last 3 months, the avarage price target is $52, with a high forecast of $NaN. The average price target represents a -25.71% change from the last price of $70.
Disclaimer: This is not investment advice. Don't use price targets as the only investment indicator. Always remember to do your own thorough research and due diligence before making an investment decision.
Halozyme Therapeutics stock Price Target by analysts
Full breakdown of analysts given Halozyme Therapeutics price targets
| Analyst name & company | Analyst win rate | Publish date | Price target | Price when posted | Source | Historical targets |
|---|---|---|---|---|---|---|
Joseph Catanzaro Piper Sandler | 0% 0/2 | 11 months ago | $52 -25.71% downside | $46.72 | StreetInsider | Previous targets (1) |
Mitchell Kapoor H.C. Wainwright | 0% 0/1 | over 1 year ago | $65 -7.14% downside | $51.44 | StreetInsider | Previous targets (0) |
Joseph Catanzaro Piper Sandler | 0% 0/2 | over 1 year ago | $51 -27.14% downside | $51.44 | TheFly | Previous targets (1) |
Corinne Jenkins Goldman Sachs | 0% 0/1 | over 1 year ago | $44 -37.14% downside | $51.44 | TheFly | Previous targets (0) |
Unknown Leerink Partners | N/A | over 2 years ago | $61 -12.85% downside | $55.7 | Benzinga | N/A |
Unknown Morgan Stanley | N/A | almost 3 years ago | $65 -7.14% downside | $58.63 | Benzinga | N/A |
Unknown Wells Fargo | N/A | almost 3 years ago | $65 -7.14% downside | $55.54 | Benzinga | N/A |
Unknown J.P. Morgan | N/A | almost 3 years ago | $54 -22.85% downside | $52.74 | Benzinga | N/A |
Halozyme Therapeutics Financial Estimates
Halozyme Therapeutics Revenue Estimates
Halozyme Therapeutics EBITDA Estimates
Halozyme Therapeutics Earnings per Share Estimates
| Passed | Analyst forecast | ||||||
|---|---|---|---|---|---|---|---|
| Metric | 12/31/2021 | 12/31/2022 | 12/31/2023 | 12/31/2025 | 12/31/2026 | 12/31/2027 | 12/31/2028 |
Revenue
% change YoY
| $443.31M N/A | $660.11M 48.90% | $829.25M 25.62% | Avg: $1.15B Low: $1.12B High: $1.20B avg. 39.20% | Avg: $1.39B Low: $1.34B High: $1.45B avg. 20.66% | Avg: $1.63B Low: $1.57B High: $1.71B avg. 17.52% | Avg: $1.74B Low: $1.67B High: $1.82B avg. 6.37% |
Net Income
% change YoY
| $402.71M N/A | $202.12M -49.80% | $281.59M 39.31% | Avg: $517.28M Low: $472.37M High: $637.43M avg. 83.69% | Avg: $664.16M Low: $713.92M High: $825.31M avg. 28.39% | Avg: $1.05B Low: $1.00B High: $1.11B avg. 58.40% | Avg: $1.13B Low: $1.08B High: $1.20B avg. 8.09% |
EBITDA
% change YoY
| $275.90M N/A | $310.67M 12.60% | $451.94M 45.47% | Avg: $414.77M Low: $404.04M High: $432.64M avg. -8.22% | Avg: $500.47M Low: $482.22M High: $523.13M avg. 20.66% | Avg: $588.20M Low: $566.75M High: $614.84M avg. 17.52% | Avg: $625.71M Low: $602.89M High: $654.04M avg. 6.37% |
EPS
% change YoY
| $2.86 N/A | $1.48 -48.25% | $2.13 43.91% | Avg: $4.15 Low: $3.52 High: $4.75 avg. 94.70% | Avg: $5.68 Low: $5.32 High: $6.15 avg. 36.91% | Avg: $7.84 Low: $7.47 High: $8.3 avg. 38.07% | Avg: $8.48 Low: $8.07 High: $8.97 avg. 8.09% |
Operating Expenses
% change YoY
| $85.99M N/A | $253.28M 194.52% | $299.31M 18.17% | Avg: $248.39M Low: $241.97M High: $259.10M avg. -17.01% | Avg: $299.72M Low: $288.79M High: $313.29M avg. 20.66% | Avg: $352.26M Low: $339.41M High: $368.21M avg. 17.52% | Avg: $374.72M Low: $361.06M High: $391.69M avg. 6.37% |
FAQ
What is Halozyme Therapeutics stock earnings growth forecast?
Wall Street analysts estimate the annual average earnings growth rate of 44.65% in 2025-2028.
We have gathered data from 6 analysts. Their low estimate is 472.37M, average is 517.28M and high is 637.43M.
What is Halozyme Therapeutics stock revenue growth forecast?
Wall Street analysts forecast annual average revenue growth of 20.94% in 2025-2028.
We have gathered data from 7 analysts. Their low revenue estimate is $1.12B, average is $1.15B and high is $1.20B.
What is Halozyme Therapeutics stock earnings per share growth forecast?
Wall Street analysts forecast annual average earnings growth of 44.44% in 2025-2028.
We have gathered data from 6 analysts. Their low earnings per share estimate is $3.52, average is $4.15 and high is $4.75.
What is the best performing analyst?
In the last twelve months 1 analysts have been covering Halozyme Therapeutics stock. The most successful analyst is Joseph Catanzaro.